Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.87 |
| ▸ | LMNA | P02545 | 2/20 | 0.87 |
| ▸ | TP53 | P04637 | 4/20 | 0.80 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | GAA | P10253 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905608 | 0.94 | MAPT (0.86) | MAPTALDH1A1LMNATP53HPGD | |
| SCHEMBL4902617 | 0.94 | MAPT (1.00) | MAPTALDH1A1LMNATP53HPGD | |
| SCHEMBL4911109 | 0.94 | MAPT (1.00) | MAPTALDH1A1LMNATP53HPGD | |
| SCHEMBL4914125 | 0.93 | MAPT (1.00) | MAPTALDH1A1LMNATP53HPGD | |
| SCHEMBL4913742 | 0.93 | MAPT (1.00) | MAPTALDH1A1LMNATP53HPGD | |
| SCHEMBL4911741 | 0.92 | MAPT (0.98) | MAPTALDH1A1LMNATP53HPGD | |
| SCHEMBL4506171 | 0.92 | MAPT (0.76) | MAPTALDH1A1LMNATP53HPGD | |
| SCHEMBL4908621 | 0.92 | ALDH1A1 (0.90) | MAPTALDH1A1LMNATP53HPGD | |
| SCHEMBL4526218 | 0.91 | MAPT (0.75) | MAPTALDH1A1LMNATP53HPGD | |
| SCHEMBL4520178 | 0.90 | MAPT (0.74) | MAPTALDH1A1LMNATP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221185-A1 | Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | claimed |
| US-20080221185-A1 | Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| US-20080221185-A1 | Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| US-20080221185-A1 | Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| WO-2007014762-A2 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221185-A1 | Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | SLC18A2, SLC6A3, SLC1A2 | MAPT 277/4885ALDH1A1 1028/4885LMNA 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.